Erudio Healtherudio.com
Sponsor
Chia Tai Tianqing Pharmaceutical Group trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Chia Tai Tianqing Pharmaceutical Group: APEX-Breast01. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| APEX-Breast01 NCT06561607 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HER2 low-expressing recurrent/metastatic breast cancer | Phase 3 | 40 | 12 | Focused | Nov 4, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ETER100 NCT04523272 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. StandardView → | first-line advanced renal cell carcinoma | Phase 3 | Standard | View | |||
| CAMPASS NCT04964479 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. FocusedView → | PD-L1-positive advanced non-small-cell lung cancer | Phase 3 | Focused | View | |||
| TQB2102-II-04 NCT06767800 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. FocusedView → | locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma | Phase 2 | Focused | View | |||